Diamyd Medical AB (FRA:DMN) Shiller PE Ratio: (As of Sep. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DMN Diamyd Medical AB FRA:DMN
38 GF Score
Price €0.07
GF Value €0.07
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Diamyd Medical AB  (FRA:DMN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Diamyd Medical AB Shiller PE Ratio Related Terms


Diamyd Medical AB Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Diamyd Medical AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB Shiller PE Ratio Chart

Diamyd Medical AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Diamyd Medical AB Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:DMN vs VRTX, REGN, MRNA: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Diamyd Medical AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Shiller PE Ratio falls into.


FRA:DMN
38GF Score
Diamyd Medical AB FRA:DMN
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamyd Medical AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Diamyd Medical AB's E10 for the quarter that ended in May. 2026 is calculated as:

For example, Diamyd Medical AB's adjusted earnings per share data for the three months ended in May. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of May. 2026 (Change)*Current CPI (May. 2026)
=-0.074/134.1100*134.1100
=-0.074

Current CPI (May. 2026) = 134.1100.

Diamyd Medical AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201608 -0.015 100.968 -0.020
201611 -0.010 101.517 -0.013
201702 -0.018 102.037 -0.024
201705 -0.030 102.679 -0.039
201708 -0.010 103.138 -0.013
201711 -0.020 103.413 -0.026
201802 -0.020 103.678 -0.026
201805 -0.019 104.632 -0.024
201808 -0.019 105.197 -0.024
201811 -0.019 105.443 -0.024
201902 -0.019 105.641 -0.024
201905 -0.009 106.895 -0.011
201908 -0.013 106.716 -0.016
201911 -0.009 107.345 -0.011
202002 0.046 106.742 0.058
202005 -0.009 106.882 -0.011
202008 -0.019 107.571 -0.024
202011 0.142 107.549 0.177
202102 0.019 108.190 0.024
202105 -0.048 108.838 -0.059
202108 -0.038 109.780 -0.046
202111 -0.048 111.069 -0.058
202202 -0.009 112.834 -0.011
202205 -0.019 116.746 -0.022
202208 -0.055 120.573 -0.061
202211 -0.036 123.803 -0.039
202302 -0.026 126.321 -0.028
202305 -0.026 128.034 -0.027
202308 -0.044 129.560 -0.046
202311 -0.034 130.958 -0.035
202402 -0.027 132.046 -0.027
202405 -0.034 132.818 -0.034
202408 -0.044 132.052 -0.045
202411 -0.034 133.000 -0.034
202502 -0.035 133.744 -0.035
202505 -0.037 133.064 -0.037
202508 -0.027 133.440 -0.027
202511 -0.036 133.340 -0.036
202602 -0.028 134.410 -0.028
202605 -0.074 134.110 -0.074

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued. The current stock price of €0.07 is trading 1.3% below its estimated GF Value™ of €0.07. GuruFocus considers Diamyd Medical AB to be Fairly Valued.

Key valuation signals for FRA:DMN:

  • Shiller PE Ratio:
  • GF Value™: €0.07 vs. price of €0.07 (1.3% below fair value)
  • GF Score™: 38/100 with 3 warning signs

No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diamyd Medical AB Business Description

Other Exchanges DMYD B:Sweden
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
38GF Score

Get the complete analysis for FRA:DMN

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.07
GF Value